Radiofrequency ablation of renal tumors.

Brian Matlaga, Ronald J. Zagoria, Peter E. Clark, M. Craig Hall

Research output: Contribution to journalArticle

Abstract

Radiofrequency ablation (RFA) of renal tumors is a relatively new treatment modality in the armamentarium of urologic surgeons. One of the challenges of this technique is attaining a zone of tissue destruction sufficient enough to kill the targeted tumor. Technologic innovations have aided in this effort. The clinical experience with RFA of renal tumors suggests that small, exophytic tumors may be more readily ablated. Although there is much optimism with regard to this technology, further study is required to better define the oncologic efficacy and refine proper patient selection.

Original languageEnglish (US)
Pages (from-to)39-44
Number of pages6
JournalCurrent Urology Reports
Volume5
Issue number1
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Kidney
Neoplasms
Patient Selection
Technology
Therapeutics
Surgeons
Optimism

ASJC Scopus subject areas

  • Urology

Cite this

Matlaga, B., Zagoria, R. J., Clark, P. E., & Hall, M. C. (2004). Radiofrequency ablation of renal tumors. Current Urology Reports, 5(1), 39-44.

Radiofrequency ablation of renal tumors. / Matlaga, Brian; Zagoria, Ronald J.; Clark, Peter E.; Hall, M. Craig.

In: Current Urology Reports, Vol. 5, No. 1, 02.2004, p. 39-44.

Research output: Contribution to journalArticle

Matlaga, B, Zagoria, RJ, Clark, PE & Hall, MC 2004, 'Radiofrequency ablation of renal tumors.', Current Urology Reports, vol. 5, no. 1, pp. 39-44.
Matlaga B, Zagoria RJ, Clark PE, Hall MC. Radiofrequency ablation of renal tumors. Current Urology Reports. 2004 Feb;5(1):39-44.
Matlaga, Brian ; Zagoria, Ronald J. ; Clark, Peter E. ; Hall, M. Craig. / Radiofrequency ablation of renal tumors. In: Current Urology Reports. 2004 ; Vol. 5, No. 1. pp. 39-44.
@article{7e51b1086e314763a8000a64f88eb888,
title = "Radiofrequency ablation of renal tumors.",
abstract = "Radiofrequency ablation (RFA) of renal tumors is a relatively new treatment modality in the armamentarium of urologic surgeons. One of the challenges of this technique is attaining a zone of tissue destruction sufficient enough to kill the targeted tumor. Technologic innovations have aided in this effort. The clinical experience with RFA of renal tumors suggests that small, exophytic tumors may be more readily ablated. Although there is much optimism with regard to this technology, further study is required to better define the oncologic efficacy and refine proper patient selection.",
author = "Brian Matlaga and Zagoria, {Ronald J.} and Clark, {Peter E.} and Hall, {M. Craig}",
year = "2004",
month = "2",
language = "English (US)",
volume = "5",
pages = "39--44",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Radiofrequency ablation of renal tumors.

AU - Matlaga, Brian

AU - Zagoria, Ronald J.

AU - Clark, Peter E.

AU - Hall, M. Craig

PY - 2004/2

Y1 - 2004/2

N2 - Radiofrequency ablation (RFA) of renal tumors is a relatively new treatment modality in the armamentarium of urologic surgeons. One of the challenges of this technique is attaining a zone of tissue destruction sufficient enough to kill the targeted tumor. Technologic innovations have aided in this effort. The clinical experience with RFA of renal tumors suggests that small, exophytic tumors may be more readily ablated. Although there is much optimism with regard to this technology, further study is required to better define the oncologic efficacy and refine proper patient selection.

AB - Radiofrequency ablation (RFA) of renal tumors is a relatively new treatment modality in the armamentarium of urologic surgeons. One of the challenges of this technique is attaining a zone of tissue destruction sufficient enough to kill the targeted tumor. Technologic innovations have aided in this effort. The clinical experience with RFA of renal tumors suggests that small, exophytic tumors may be more readily ablated. Although there is much optimism with regard to this technology, further study is required to better define the oncologic efficacy and refine proper patient selection.

UR - http://www.scopus.com/inward/record.url?scp=2142816617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142816617&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 39

EP - 44

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 1

ER -